Eloxx Pharmaceuticals, Inc. (ELOX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | -34.41 Million USD | 47.86% |
| 2021 | -66.01 Million USD | -97.33% |
| 2020 | -33.45 Million USD | 33.82% |
| 2019 | -50.55 Million USD | -6.29% |
| 2018 | -47.56 Million USD | -133.28% |
| 2017 | -20.39 Million USD | -343.95% |
| 2016 | -4.59 Million USD | 58.97% |
| 2015 | -11.19 Million USD | 38.07% |
| 2014 | -18.07 Million USD | -97.61% |
| 2013 | -9.14 Million USD | -96.71% |
| 2012 | -4.65 Million USD | 14.06% |
| 2011 | -5.41 Million USD | 31.66% |
| 2010 | -7.91 Million USD | -63.39% |
| 2009 | -4.84 Million USD | -13.11% |
| 2008 | -4.28 Million USD | -19.05% |
| 2007 | -3.59 Million USD | -8.37% |
| 2006 | -3.32 Million USD | 2.88% |
| 2005 | -3.41 Million USD | -2.94% |
| 2004 | -3.32 Million USD | 17.72% |
| 2003 | -4.03 Million USD | -77.96% |
| 2002 | -2.26 Million USD | -7.3% |
| 2001 | -2.11 Million USD | -7.26% |
| 2000 | -1.97 Million USD | 19.46% |
| 1999 | -2.44 Million USD | -111.74% |
| 1998 | -1.15 Million USD | -11041.87% |
| 1997 | -10.37 Thousand USD | -32.83% |
| 1996 | -7810.00 USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q2 | -4.14 Million USD | 24.49% |
| 2023 Q3 | -3.63 Million USD | 12.15% |
| 2023 Q1 | -5.48 Million USD | 9.04% |
| 2022 Q2 | -10.29 Million USD | 6.0% |
| 2022 Q4 | -6.02 Million USD | 15.6% |
| 2022 Q3 | -7.14 Million USD | 30.63% |
| 2022 FY | -34.41 Million USD | 47.86% |
| 2022 Q1 | -10.95 Million USD | 5.82% |
| 2021 Q4 | -11.63 Million USD | -13.52% |
| 2021 FY | -66.01 Million USD | -97.33% |
| 2021 Q1 | -8.41 Million USD | -44.92% |
| 2021 Q2 | -35.72 Million USD | -324.64% |
| 2021 Q3 | -10.24 Million USD | 71.33% |
| 2020 Q1 | -13.76 Million USD | -19.84% |
| 2020 Q4 | -5.8 Million USD | 7.78% |
| 2020 Q3 | -6.29 Million USD | 17.01% |
| 2020 FY | -33.45 Million USD | 33.82% |
| 2020 Q2 | -7.58 Million USD | 44.9% |
| 2019 FY | -50.55 Million USD | -6.29% |
| 2019 Q1 | -11.97 Million USD | 15.14% |
| 2019 Q2 | -14.31 Million USD | -19.49% |
| 2019 Q3 | -12.77 Million USD | 10.71% |
| 2019 Q4 | -11.48 Million USD | 10.1% |
| 2018 Q1 | -8.54 Million USD | 0.0% |
| 2018 FY | -47.56 Million USD | -133.28% |
| 2018 Q3 | -11.36 Million USD | 16.12% |
| 2018 Q2 | -13.54 Million USD | -58.43% |
| 2018 Q4 | -14.11 Million USD | -24.24% |
| 2017 Q1 | -341.88 Thousand USD | 77.32% |
| 2017 Q3 | -627.44 Thousand USD | -17.73% |
| 2017 FY | -20.39 Million USD | -343.95% |
| 2017 Q2 | -532.96 Thousand USD | -55.89% |
| 2016 Q3 | -2.21 Million USD | -58.29% |
| 2016 Q1 | -4.88 Million USD | -30.09% |
| 2016 Q2 | -1.39 Million USD | 71.44% |
| 2016 Q4 | -1.5 Million USD | 31.8% |
| 2016 FY | -4.59 Million USD | 58.97% |
| 2015 Q3 | -1.15 Million USD | -25.28% |
| 2015 Q2 | -919.02 Thousand USD | 24.98% |
| 2015 Q4 | -3.75 Million USD | -226.41% |
| 2015 Q1 | -1.22 Million USD | 88.6% |
| 2015 FY | -11.19 Million USD | 38.07% |
| 2014 Q4 | -10.74 Million USD | -107.25% |
| 2014 Q1 | -2.12 Million USD | -33.99% |
| 2014 Q3 | -5.18 Million USD | -41.02% |
| 2014 Q2 | -3.67 Million USD | -72.73% |
| 2014 FY | -18.07 Million USD | -97.61% |
| 2013 Q3 | -1.75 Million USD | -65.35% |
| 2013 FY | -9.14 Million USD | -96.71% |
| 2013 Q4 | -1.58 Million USD | 9.35% |
| 2013 Q2 | -1.06 Million USD | -1.51% |
| 2013 Q1 | -1.04 Million USD | 19.67% |
| 2012 Q2 | -1.24 Million USD | -12.32% |
| 2012 Q4 | -1.3 Million USD | -4.32% |
| 2012 FY | -4.65 Million USD | 14.06% |
| 2012 Q3 | -1.24 Million USD | -0.06% |
| 2012 Q1 | -1.1 Million USD | 23.86% |
| 2011 Q3 | -1.28 Million USD | -2.22% |
| 2011 Q2 | -1.25 Million USD | 8.44% |
| 2011 Q1 | -1.36 Million USD | 9.12% |
| 2011 Q4 | -1.45 Million USD | -13.75% |
| 2011 FY | -5.41 Million USD | 31.66% |
| 2010 Q4 | -1.5 Million USD | 31.76% |
| 2010 FY | -7.91 Million USD | -63.39% |
| 2010 Q3 | -2.2 Million USD | -27.58% |
| 2010 Q2 | -1.72 Million USD | -54.17% |
| 2010 Q1 | -1.12 Million USD | -10.69% |
| 2009 Q2 | -1.22 Million USD | -22.71% |
| 2009 FY | -4.84 Million USD | -13.11% |
| 2009 Q4 | -1.01 Million USD | -2.97% |
| 2009 Q3 | -983.71 Thousand USD | 19.66% |
| 2009 Q1 | -997.73 Thousand USD | 18.77% |
| 2008 FY | -4.28 Million USD | -19.05% |
| 2008 Q3 | -834.25 Thousand USD | 15.26% |
| 2008 Q4 | -1.22 Million USD | -47.24% |
| 2008 Q2 | -984.48 Thousand USD | 22.6% |
| 2008 Q1 | -1.27 Million USD | -30.88% |
| 2007 FY | -3.59 Million USD | -8.37% |
| 2007 Q4 | -971.85 Thousand USD | -162.16% |
| 2007 Q1 | -822.23 Thousand USD | 29.22% |
| 2007 Q2 | -725.64 Thousand USD | 11.75% |
| 2007 Q3 | -370.7 Thousand USD | 48.91% |
| 2006 Q4 | -1.16 Million USD | -90.02% |
| 2006 Q3 | -611.38 Thousand USD | 24.16% |
| 2006 Q2 | -806.13 Thousand USD | -8.64% |
| 2006 Q1 | -742.03 Thousand USD | 21.2% |
| 2006 FY | -3.32 Million USD | 2.88% |
| 2005 Q3 | -929.49 Thousand USD | -47.43% |
| 2005 Q2 | -630.48 Thousand USD | 31.62% |
| 2005 FY | -3.41 Million USD | -2.94% |
| 2005 Q4 | -941.68 Thousand USD | -1.31% |
| 2005 Q1 | -922.02 Thousand USD | -14.08% |
| 2004 Q2 | -767.95 Thousand USD | -25.79% |
| 2004 Q1 | -610.51 Thousand USD | 32.06% |
| 2004 Q3 | -731.48 Thousand USD | 4.75% |
| 2004 Q4 | -808.24 Thousand USD | -10.49% |
| 2004 FY | -3.32 Million USD | 17.72% |
| 2003 Q2 | -487.23 Thousand USD | 8.43% |
| 2003 Q3 | -1.41 Million USD | -189.67% |
| 2003 FY | -4.03 Million USD | -77.96% |
| 2003 Q4 | -898.67 Thousand USD | 36.33% |
| 2003 Q1 | -532.09 Thousand USD | 25.28% |
| 2002 Q1 | -495.49 Thousand USD | 34.06% |
| 2002 Q3 | -537.18 Thousand USD | -45.35% |
| 2002 Q4 | -712.08 Thousand USD | -32.56% |
| 2002 FY | -2.26 Million USD | -7.3% |
| 2002 Q2 | -369.59 Thousand USD | 25.41% |
| 2001 Q3 | -497.72 Thousand USD | -19.75% |
| 2001 Q2 | -415.62 Thousand USD | 8.44% |
| 2001 Q4 | -751.42 Thousand USD | -50.97% |
| 2001 FY | -2.11 Million USD | -7.26% |
| 2001 Q1 | -453.91 Thousand USD | 21.6% |
| 2000 FY | -1.97 Million USD | 19.46% |
| 2000 Q3 | -522.57 Thousand USD | 16.08% |
| 2000 Q4 | -578.95 Thousand USD | -10.79% |
| 2000 Q1 | -827.37 Thousand USD | -106.84% |
| 2000 Q2 | -622.68 Thousand USD | 24.74% |
| 1999 Q4 | -400 Thousand USD | 0.0% |
| 1999 FY | -2.44 Million USD | -111.74% |
| 1998 FY | -1.15 Million USD | -11041.87% |
| 1997 FY | -10.37 Thousand USD | -32.83% |
| 1996 FY | -7810.00 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| America Great Health | -492.64 Thousand USD | -6886.587% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -261.62% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | -14.757% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 48.738% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | -117.251% |
| Better Therapeutics, Inc. | -38.26 Million USD | 10.044% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 18.194% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | -187.543% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | -1.699% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 68.267% |
| Evolutionary Genomics, Inc. | -2.01 Million USD | -1608.731% |
| Finch Therapeutics Group, Inc. | -34 Million USD | -1.226% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 26.692% |
| Innovation1 Biotech Inc. | -1.36 Million USD | -2417.139% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | -72.619% |
| Molecular Templates, Inc. | -10.46 Million USD | -228.865% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | -144.959% |
| NexImmune, Inc. | -29.19 Million USD | -17.904% |
| Orgenesis Inc. | -53.63 Million USD | 35.829% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 32.899% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -44017.308% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -113.183% |
| Scopus BioPharma Inc. | -11.71 Million USD | -193.806% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 93.175% |
| Statera Biopharma, Inc. | -98.34 Million USD | 65.001% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -398.971% |
| Trevena, Inc. | -35.28 Million USD | 2.463% |
| Vaxxinity, Inc. | -58.28 Million USD | 40.947% |
| Vaccinex, Inc. | -22.88 Million USD | -50.4% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -3187.462% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 32.103% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -373.894% |